Placeholder Banner

Adopting foreign price controls “prevents investors from being able to invest, and inventors from being able to invent.”

February 3, 2020
Media Contact
Author-Profile-Andrew-Segerman

In a new video, Alex Karnal, a life science investor and partner at Deerfield Management, shares why investing in new cures and treatments is personal, and he explains how President Trump’s plan to import foreign price controls would have an “absolutely chilling” effect on investments in transformational, life-saving therapies. 

 

“President Trump, we have got to lower drug prices at the pharmacy counter right now. In order to do that, we need four key groups to come together … and derive a holistic solution to treat the disease versus using foreign reference pricing as a scheme to focus on a single symptom.”

To learn more about the flaws of importing foreign price controls, visit bio.org/save-cures.

Additional resources:

###

Discover More
In a new video, Cynthia Bens, patient advocate and Senior Vice President of Public Policy at the Personalized Medicine Coalition, shares her views on how adopting foreign price controls for prescription medicines will impact patients in the U.S. …
Ahead of tonight’s State of the Union Address, Jim Greenwood, President and CEO of the Biotechnology Innovation Organization, shared what he hopes President Trump will say to America’s patients counting on the development of new medicines and cures,…
Rachel King is co-founder and CEO of GlycoMimetics, a biotech company based in Rockville, Maryland that is working hard to develop new treatments for patients with various diseases of the blood. In a new video, Mrs. King explains why President Trump…